Get Wegovy Online — From $179/Month
Real Wegovy prescribed by licensed US clinicians. 14.9% avg body weight on average. FDA-approved high-dose semaglutide brand for weight loss.
✓ No insurance needed · ✓ Ships in 5-7 days · ✓ Cancel anytime
Wegovy (semaglutide 2.4 mg) is the FDA-approved high-dose semaglutide brand for chronic weight management. Approved in 2021 and expanded in 2024 for cardiovascular risk reduction, Wegovy produces an average 14.9% body weight loss over 68 weeks at maintenance dose.
Overview
Wegovy is the same molecule as Ozempic — semaglutide — but at a higher maximum dose (2.4 mg/week vs. Ozempic's 2.0 mg). It is approved specifically for chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity. In 2024 the FDA expanded the indication to cardiovascular event reduction in adults with established heart disease and obesity, based on the SELECT trial.
Wegovy is administered as a once-weekly subcutaneous injection using a single-dose pre-filled pen. Five doses are available (0.25, 0.5, 1.0, 1.7, 2.4 mg) for a 16-week titration schedule.
How Wegovy Works
Wegovy is a long-acting GLP-1 receptor agonist. It activates GLP-1 receptors in the brain, stomach, and pancreas to reduce appetite, slow gastric emptying, and improve glucose metabolism. The fatty-acid linker on the semaglutide molecule binds to albumin in the bloodstream, extending half-life to about 7 days — enabling once-weekly dosing.
Dosing & Schedule
Wegovy follows a strict 16-week titration to the 2.4 mg maintenance dose:
- Weeks 1-4: 0.25 mg/week
- Weeks 5-8: 0.5 mg/week
- Weeks 9-12: 1.0 mg/week
- Weeks 13-16: 1.7 mg/week
- Weeks 17+: 2.4 mg/week (maintenance)
If side effects are intolerable, the prescriber can pause titration or hold at a lower dose. Some patients respond well at 1.7 mg and never escalate to 2.4 mg.
Effectiveness — Trial Data
STEP-1 trial (68 weeks, n=1,961 adults with overweight/obesity, no diabetes):
- Wegovy 2.4 mg group: 14.9% average weight loss
- Placebo group: 2.4% loss
- 50.5% of Wegovy users lost ≥15%; 32% lost ≥20%
SELECT trial (cardiovascular outcomes): 20% reduction in major adverse cardiovascular events vs. placebo over a median 39 months in adults with prior heart disease + obesity.
Side Effects
Common side effects (≥10% in STEP-1):
- Nausea (44%)
- Diarrhea (30%)
- Vomiting (24%)
- Constipation (24%)
- Abdominal pain (20%)
- Headache (14%)
- Fatigue (11%)
Most GI effects peak during titration and improve by month 4-6. About 7% of trial participants discontinued due to side effects.
Cost — How Much Wegovy Costs in 2026
Wegovy list price is $1,349 per month without insurance. Most commercial insurance plans require prior authorization. The NovoCare savings card can reduce out-of-pocket cost to as low as $0/month for some commercially insured patients (up to $200/mo discount otherwise). Without insurance, the cheapest path to the same active ingredient is compounded semaglutide from licensed telehealth providers, starting at $179/mo.
Who Is Wegovy For?
Wegovy is FDA-approved for:
- Adults with BMI ≥30, or BMI ≥27 with weight-related comorbidity
- Adolescents 12+ with BMI in the 95th+ percentile (separate trial: STEP TEENS)
- Adults with established cardiovascular disease + overweight/obesity (CV risk reduction)
Wegovy Alternatives
If Wegovy is not the right fit:
- Zepbound (tirzepatide) — stronger weight loss results
- Saxenda (liraglutide) — daily injection, older mechanism
- Contrave — oral non-GLP-1 option
- Compounded semaglutide via online providers — same active ingredient at lower cost